Gwyneth Paltrow and Serena Williams are both fans of neuromodulation – but what is it and how does it work?
For most, the idea that you might don a headset to zap your depression away or use electromagnetic pulses to sharpen your cognition seems better placed in a science fiction novel from the 1930s than modern neuroscience, but these kinds of treatments are more common than you might think.
In fact, you can now buy 'vagus reset' gadgets to practice what's broadly referred to as 'neurostimulation' or 'neuromodulation' at home – Instagram and Tiktok are awash with ads for them. And for more intense forms of this kind of technology, a quick online search will deliver a range of private clinics offering 'repetitive transcranial magnetic stimulation' to treat depression and anxiety.
Tennis legend Serena Williams and Goop founder Gwyneth Paltrow are among those who've checked into a private facility to undergo a treatment like this. The athlete recently shared a sponsored Instagram post about her 'ExoMind' journey, describing the treatment as a form of self care. Wellness magnate Paltrow posted a similar story on her Instagram, showing a glowing device attached to her head while she lay on a table.
The company responsible for ExoMind describes the treatment as 'a workout for your mind. An FDA-cleared for the treatment of depression'. The company also offers treatments that use electric pulses to tone and strengthen muscles all over the body – from the stomach to the pelvic floor.
But naturally, both Williams' and Paltrow's Instagram posts have prompted some confusion about possible uses for neuromodulation, delivery methods and who should be using technology like this. Do we need to be nudging our brains with electrical stimuli for improved 'mental fitness'? Or should we just stick with mindfulness apps and fish oil supplements for better brain health?
Furthermore, is stimulating the brain actually a serious cure for depression? Do you need to visit a clinic or will an at-home headset deliver the same results? And most importantly, is this all safe?
Neurostimulation is the act of stimulating the brain, spinal cord or peripheral nerves to modulate neuronal activity. There are a variety of ways to do this and types of neurostimulation vary. For example, a headset that you can buy online without a prescription that promises to 'reset your vagus nerve' is not the same as an in-clinic transcranial stimulation session delivered by a qualified practitioner.
The Flow headset, for example, sends the equivalent current of an AA battery directly to the dorsolateral prefrontal cortex, 'targeting depression at its source to help relieve symptoms'. Rival company Neurosym claims that its device emits precise electrical pulses for 'safe stimulation of vagus nerve fibres'. The company isn't clear on how this approach differs from Flow's, but it does claim that the device activates the parasympathetic nervous system to 'effectively manage chronic pain, fibromyalgia, gut problems, long-covid symptoms, inflammation, POTS symptoms, fatigue, sleep issues, HRV issues, ADHD symptoms, stress, anxious and depressive thoughts and more'. Quite the list of claims.
Pulsetto, another headset that you can use at home, also describes itself as a 'vagus stimulator'. Pulsetto technology uses the lowest form of bluetooth energy – ultra low radiofrequency energy (ULRE) – which according to the brand, 'passes safely into the body to biohack your parasympathetic nervous system'.
'These headsets have great branding but in reality you don't know the exact effects that treatment is going to have on you,' says Adam O'Hagan, specialist rTMS practitioner and coordinator at Priory Wellbeing Centre Harley Street.
'The do-it-yourself kits have shown to be effective but not as much as in controlled settings. Some headsets use rTMS in low levels but they're very different to what we do. They can be more cost effective but use different technologies and these can be significantly less effective.'
Read more: 14 best mindfulness apps to help you keep calm during a crisis
The kind of treatment offered at Priory differs vastly from headsets like Flow and Neurosym – technologies that you can easily buy online albeit for a high price point. Technically, all treatments fall under the umbrella of neurostimulation, but there are significant differences when it comes to the technology and frequencies used, and the applications and results.
The idea with both in-clinic treatments and do-it-yourself headsets is to nudge the areas of the brain that are responsible for emotional regulation, cognitive function and self-control. These areas can often become under-active and this lack of activity is associated with low mood, anxiety, depression and behavioural disorders. Neurostimulation devices generate magnetic pulses to induce electrical currents in the brain, stimulating under-active brain regions.
'An in-clinic session can last about 30 minutes and is typically recommended for treatment-resistant depression, obsessive compulsive disorder, significant eating disorders and anxiety symptoms. The intensity of the machine used is much higher and the treatment is administered by a trained professional,' explains O'Hagan.
'During an rTMS session, electromagnetic coils are placed on your scalp in order to deliver magnetic pulses to your brain. The treatment specifically targets areas of the brain that are involved in mood control, which means it can help to alleviate the symptoms of your mental health conditions and improve wellbeing.'
'The side effects are extremely minimal compared to other treatments such as medication, so it's a much safer and less invasive solution. Some patients can see results after five sessions or around the halfway mark in the treatment plan,' he adds.
It's worth noting that rTMS is very different to electroconvulsive therapy, or ECT, which sends a seizure-inducing current through the brain. Doctors have used ECT for almost a century, and though it's still used in some cases, it remains a controversial and rudimentary treatment.
Read more: I tried hypnotherapy to cure my anxiety and noticed results after just one session
At the other end of the neurostimulation spectrum are home devices – headsets that deliver a mild electrical current to the brain and that can be worn daily on the head or neck. These devices offer 'improved mental fitness' – a catch-all term that seems to comprise several indicators of good health such as boosted mood, lower anxiety levels, improved memory and cognition, and better focus.
The biohacking and longevity crowd are especially keen on the idea of fitness for your mind – Bryan Johnson wears a Pulsetto headset in his Netflix documentary Don't Die. However, Dr Faye Begeti, practising neurology doctor at Oxford University Hospitals and author of The Phone Fix, explains that the term mental fitness is actually quite vague if we're discussing the true benefits of these devices.
'The term 'mental fitness' allows companies to market these devices without clear scientific backing,' she says. 'While some biohackers report subjective benefits, scientific evidence supporting any substantial long term improvement from these devices is weak.
'Established good brain habits such as adequate sleep, regular exercise, learning new skills to build cognitive reserve, and stress management have stronger evidence for improving brain function over time. Expecting dramatic improvements in memory, focus, or productivity from neurostimulation devices is likely unrealistic.'
But as mental health issues such as anxiety and depression continue to affect large swathes of the UK population, people are looking for alternative sources of support – particularly within biohacking and functional medicine. So despite scant evidence that at-home devices can help – and their hefty price tags – neurostimulation headsets have become incredibly popular.
This might have something to do with the fact that social media is currently flooded with instructional videos on 'how to reset your vagus nerve'. These techniques range from simple massage and acupressure to recommendations for headsets like the Neurosym or Pulsetto.
'The vagus nerve 'reset' trend is a mix of science and misinformation,' explains Dr Begeti. The vagus nerve plays a key role in the parasympathetic nervous system, which helps regulate stress, digestion and heart rate. Activities like spending time in nature, meditation, and breathing exercises can stimulate vagal tone, which may have calming effects – but calling it a 'reset' or a 'detox' is misleading. The nervous system is not something that needs 'resetting' in the way social media often suggests.'
'The issue is that social media often oversimplifies complex neuroscience, making it seem like a single technique is a quick hack for mental health. Instead, it's important to have multiple tools in your toolkit for managing difficult emotions while also seeking professional advice when needed,' she adds.
Read more: An expert says you should be doing these four breathing exercises every day
As Dr Begeti says, there's no one trick to eliminate mental health issues. A healthy diet of gut-friendly foods, regular exercise, quality sleep and other techniques like breathwork, yoga and time in nature can all have a positive impact on the brain and nervous system when combined. In isolation, a neurostimulation device won't make much difference if you're not taking good care of yourself.
However, the most recent studies on the effects of clinical rTMS are promising. 'We are witnessing a growing mental health crisis,' explains O'Hagan. 'Depression is treatable, but for some people, medication and psychotherapy do not provide relief. In such cases, rTMS is a really incredible new tool.'
The important thing is not to downplay the intensity of a treatment like this. Though it's akin to tickling your brain, one should be aware of the risks. Various studies have shown that neurostimulation can help improve mood, but a small number of patients have experienced long term effects like tinnitus, cognitive impairment, behavioural changes and short term memory loss.
These outcomes are far less likely with an at-home treatment as the power generated by a wearable isn't comparable to an in-clinic rTMS treatment. However, there are still risks associated with using one. You are, after all, giving your brain a buzz, regardless of the dose.
'The biggest concern is that many brands do not disclose the exact stimulation parameters, making it difficult to know what effect the device is actually having. Additionally, improper use – such as applying stimulation to the wrong area of the brain – could lead to unintended effects,' says Dr Begeti.
She advises researching the frequency and intensity used in detail and checking if the device has been tested in peer-reviewed studies, rather than relying on general research. She also recommends checking for FDA approval or CE certification for specific medical conditions, as opposed to general wellness claims, and reading the instructions thoroughly.
'For low mood, anxiety and issues with feeling dysregulated, a headset could help,' says O'Hagan. However, the best course of action is to use a wearable in conjunction with other healthy habits. These devices are definitely not a magic bullet and O'Hagan recommends using them alongside other interventions like talking therapy and daily self care routines.
'Typically I wouldn't recommend them for people with clinical depression,' he says. But this is where a treatment like clinical rTMS might make a difference, particularly if you've tried other treatments and found them inconsistent or unhelpful.
Our collective understanding of mental health issues is progressing as we find new ways to support and foster good mental health and to treat chronic life-altering problems. Hacking the brain with electromagnetic pulses is clearly just the beginning. But if you're keen to become a brain biohacker yourself, be sure to cast a critical eye over claims you see online, consult with experts and always do your research before trying a new treatment.
Read more: How to spot the symptoms of burnout and treat them, according to wellbeing experts

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fast Company
4 hours ago
- Fast Company
Why we need to redefine puberty culture for Gen Z girls
The rise of misinformation aimed at young girls across digital underscores an urgent need for credible resources, empowering products, and emotionally safe communities. Today's teen girls are navigating puberty and emotional development in a world no previous generation has known, one where their bodies, confidence, and mental health are influenced as much by social media algorithms as by their own biology. And it's taking a devastating toll. Popular platforms like TikTok and Instagram are proving to be part of the problem, with one in three girls acknowledging negative feelings about their body, based on what they see in their feeds, on a weekly basis. And while this is beginning earlier and earlier each year, a U.S. study revealed that by age 13, 53% of girls report being unhappy with their bodies, a figure that by age 17, rises to an alarming 78%. All of this during the crucial period when girls' self-worth, mental health, and emotional resilience are also being developed. Lack of puberty education and practical support Major surveys show many U.S. girls feel under-prepared for puberty. In one 2021 study, 74% of menstruating students (ages 13–19) had questions about their periods, yet just 43% said schools openly discussed this puberty milestone. A 2023 poll of American women found only 15% felt prepared for their first period, 48% said they were not prepared, and 21% did not understand what was happening at their first menstruation. A 2021–22 national health survey found 31% of girls (ages 12–17) reported anxiety symptoms and 25% reported depression. Feelings of isolation and stigma are common. In a representative teen poll, 45% of girls said they'd been 'too ashamed or embarrassed' to seek help when they had questions about their bodies (e.g. puberty or menstruation). Likewise, 58% of teens agreed that society 'is not set up for them to manage puberty and menstruation with full confidence.' And here's the reality: Puberty isn't what it was 10 years ago. Menarche—a girl's first period—now arrives as young as age 9. Girls are navigating their most vulnerable stages of growth and development in a digital age with little support. Recently, Cloudstate CEO Meg Smith spent 16 months with global focus groups, conducting surveys and conversations with hundreds of Gen Z girls and their parents. By the end, one thing was clear: Girls today need a brand—and a safe space—that actually puts the needs and voices of their community first. The digital puberty space Gen Z actually wants Platforms like Cloudstate's Girl Talk Live (GTL), a first-of-its-kind digital destination designed for girls navigating puberty's emotional and social rollercoasters in today's hyper-connected world, is a necessary first step. Cloudstate understands young girls today aren't interested in a sterile medical site or a glorified product forum. Instead, they want a hype-worthy, judgment-free zone where they can ask the real stuff, connect with relatable 'big sister' mentors, and access expert-backed advice on everything from body confidence to friend drama to managing anxiety. They thrive in places that feel like their closest squad—but smarter, safer, and kinder. We are here to provide just that. But we also know that resources alone aren't enough. Some of the earliest experiences girls have with their changing bodies, like shopping for their first bra, are deeply emotional milestones too often treated as transactional. That's why we are reimagining what that moment looks and feels like. Our brand isn't just selling bras, we're creating confidence-first products designed to support a girl's emotional, physical, and mental growth. Because for girls, a bra isn't just a bra. It's an early, intimate encounter with their changing body—and it deserves care, kindness, and community to go with it. Because Gen Z girls deserve better Puberty is biologically wired to be an emotionally intense time. In the digital age, that natural vulnerability is amplified by forces girls were never meant to navigate alone. It's time brands and influencers stop offering products and advice that may be unqualified and harmful, without providing emotional support, real conversation, and a seat at the table. Gen Z girls aren't simply accepting how they should deal with puberty. They are challenging what is offered to them and demanding an experience that is better than the generations that came before. They are rewriting the rules of puberty culture…and it's time we all listen.
Yahoo
4 hours ago
- Yahoo
FDA investigates patient deaths after treatment with Sarepta's gene therapy
(Reuters) -The U.S. Food and Drug Administration said on Tuesday that it is investigating reports of two deaths due to acute liver failure in non-ambulatory Duchenne muscular dystrophy patients after receiving Sarepta Therapeutics' gene therapy, Elevidys. In June, Sarepta reported a second death in a patient who had received its gene therapy, which raised concerns about the safety and future demand for the treatment. The patients who died were a 16-year-old, weighing 70 kilograms, and a 15-year-old, weighing 50 kilograms. Both boys were non-ambulatory and their deaths occurred within 90 days after treatment, the company said in an investor call last week. The two patients showed signs of acute liver failure and were hospitalized less than two months after treatment with Elevidys, the health regulator said on Tuesday. It added that it is evaluating the need for further regulatory action. Sarepta said in an email to Reuters, "The FDA communication was triggered by our report to the FDA and our suggested update to the label to include information relating to the recent events." The U.S. prescribing information for Elevidys warns of acute liver injury but does not mention liver failure or death. Elevidys, approved by the FDA in 2024 for ambulatory Duchenne muscular dystrophy patients aged four and older, is the only gene therapy available for the disease. It carries a known risk of liver damage and was conditionally approved for non-ambulatory patients despite failing to meet the main goal in a late-stage study. Sarepta said earlier this month it was investigating both cases independently and in relation to each other to identify any common risk factors. The company has suspended its Elevidys sales forecast for 2025, halted shipments to non-ambulatory patients and is working with regulators on a new treatment plan.
Yahoo
4 hours ago
- Yahoo
BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden
The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE), IgA nephropathy, and Sjögren's syndrome. Advancements in biologics and the entry of pipeline agents with improved efficacy profiles are further fueling market expansion. LAS VEGAS, June 24, 2025 /PRNewswire/ -- DelveInsight's BAFF- and APRIL-targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as IgA nephropathy (IgAN), lupus nephritis, myasthenia gravis, systemic lupus erythematosus (SLE), Sjögren's syndrome, and other B-cell-mediated autoimmune conditions. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging BAFF- and APRIL-targeted therapies, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the BAFF- and APRIL-targeted Therapies Market Report As per DelveInsight's analysis, the total market size of BAFF- and APRIL-targeted therapies in the 7MM is expected to surge significantly by 2034. BAFF and APRIL-targeted therapies are actively being developed to address a broad spectrum of autoimmune diseases, including IgA nephropathy (IgAN), lupus nephritis, myasthenia gravis, systemic lupus erythematosus (SLE), Sjögren's syndrome, and other B-cell-mediated autoimmune conditions, offering promising new options to modulate pathogenic B-cell activity and improve patient outcomes. Leading BAFF- and APRIL-targeted therapies companies, such as Vera Therapeutics, RemeGen, Aurinia Pharmaceuticals, and others, are developing novel BAFF- and APRIL-targeted therapies that can be available in the BAFF- and APRIL-targeted therapies market in the coming years. Some of the key BAFF- and APRIL-targeted therapies in the pipeline include Atacicept, Telitacicept, AUR200, and others. In May 2025, Vera Therapeutics announced that primary endpoint results from the pivotal Phase III ORIGIN 3 trial of atacicept in Immunoglobulin A Nephropathy (IgAN) are expected in Q2 2025, with plans to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) in Q4 2025 for accelerated approval, targeting a potential PDUFA date and commercial launch in 2026. In November 2024, the European Medicines Agency (EMA) granted orphan medicine designation to Atacicept for the treatment of IgAN. In May 2024, Vera Therapeutics announced that the US FDA had granted Breakthrough Therapy Designation (BTD) to atacicept for the treatment of IgAN. The designation reflects the FDA's determination that, based on an assessment of data from the Phase IIb ORIGIN clinical trial of atacicept for IgAN, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN. Discover which indication is expected to grab the major BAFF- and APRIL-targeted therapies market share @ BAFF- and APRIL-targeted Therapies Market Report BAFF- and APRIL-targeted Therapies Market Dynamics The BAFF- and APRIL-targeted therapies market is evolving rapidly, driven by a growing understanding of B-cell biology and its role in autoimmune diseases. BAFF and APRIL are crucial for B-cell survival, maturation, and function. Overexpression of these cytokines has been implicated in diseases such as IgA nephropathy (IgAN), lupus nephritis, myasthenia gravis, systemic lupus erythematosus (SLE), Sjögren's syndrome, and other B-cell-mediated autoimmune conditions. Therapies targeting these pathways aim to modulate abnormal B-cell activity, offering more precise immunomodulatory approaches compared to broad immunosuppressants. Market interest in this space has intensified with the development of biologics like atacicept and, more recently, telitacicept. These agents work by neutralizing excess BAFF and/or APRIL, reducing pathogenic autoantibody production. The differentiated mechanism of dual targeting is believed to offer superior efficacy in certain patient subtypes, fueling competitive development programs. The market dynamics are shaped by both unmet clinical needs and strategic commercial considerations. Autoimmune diseases, particularly lupus and IgAN, have long suffered from limited treatment options with poor tolerability or efficacy. As a result, payers and clinicians are keen on alternatives that offer disease modification and long-term remission. However, safety remains a concern, especially the risk of hypogammaglobulinemia and infections due to B-cell suppression. This risk-benefit balance is a key differentiator in positioning products within the competitive landscape. Overall, the BAFF/APRIL-targeted therapy market is transitioning from experimental to established, with first-in-class and best-in-class competition intensifying. Pipeline diversity, biomarker-driven patient selection, and combinatorial strategies with other immunotherapies will be central to shaping the future landscape. As real-world evidence accumulates and regulatory agencies refine guidance, these therapies may move from niche indications to broader frontline use in autoimmune care. BAFF- and APRIL-targeted Therapies Treatment Market The landscape for BAFF- and APRIL-targeted therapies is undergoing rapid transformation, fueled by the pressing need for more precise B cell modulation in autoimmune disorders. As of 2025, no fusion proteins targeting these pathways have received FDA approval, but several promising candidates are advancing through late-stage clinical trials. This progress reflects a positive shift in the field, pointing toward more effective dual-pathway immunotherapies that could address the shortcomings of existing treatments and provide renewed hope for patients with challenging autoimmune conditions. Learn more about the BAFF- and APRIL-targeted therapies @ BAFF- and APRIL-targeted Therapies Analysis Key Emerging BAFF- and APRIL-targeted Therapies and Companies Some of the BAFF- and APRIL-targeted therapies in the pipeline include Atacicept (Vera Therapeutics), Telitacicept (RemeGen), AUR200 (Aurinia Pharmaceuticals), and others. Atacicept is an investigational fusion protein composed of the soluble form of the TACI receptor, which binds to the cytokines BAFF and APRIL—members of the TNF family involved in supporting B-cell survival and promoting the production of autoantibodies linked to autoimmune conditions such as IgAN and lupus nephritis. Vera Therapeutics views atacicept as a strong contender for best-in-class status due to its dual targeting of B cells and plasma cells to lower autoantibody levels. The drug has already been tested in over 1,500 patients across multiple indications in clinical trials. Atacicept is currently undergoing Phase III trials for the treatment of IgAN. Telitacicept, developed by RemeGen, is another fusion protein that also targets BAFF and APRIL, aiming to treat autoimmune diseases driven by B cells. It is being studied globally, including in the U.S., for conditions such as myasthenia gravis, systemic lupus erythematosus (SLE), and Sjögren's syndrome. The U.S. FDA has granted Orphan Drug Designation (ODD) and Fast Track Designation (FTD) for telitacicept in myasthenia gravis. A notable advancement in its development came in August 2024, when the first U.S. patient was enrolled in a global Phase III trial for generalized myasthenia gravis. The anticipated launch of these emerging therapies are poised to transform the BAFF- and APRIL-targeted therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the BAFF- and APRIL-targeted therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about BAFF- and APRIL-targeted therapies clinical trials, visit @ BAFF- and APRIL-targeted Therapies Treatment BAFF- and APRIL-targeted Therapies Overview BAFF and APRIL, both part of the TNF family, are key regulators of B cell survival, development, and antibody class switching through their interactions with the receptors BAFF-R, TACI, and BCMA. When the BAFF/APRIL pathway becomes dysregulated, often due to ligand overexpression, it can trigger abnormal B cell activation and drive the development of autoimmune diseases. BAFF mainly signals through BAFF-R, activating both the classical and alternative NF-κB pathways, while APRIL binds to TACI and BCMA and also interacts with heparan sulfate proteoglycans to amplify B cell responses. Given their pivotal role in immune system regulation, BAFF and APRIL have emerged as promising therapeutic targets. Clinical studies have shown that inhibiting BAFF can significantly reduce disease activity in various autoimmune conditions by curbing harmful B-cell activity and helping to restore immune homeostasis. BAFF- and APRIL-targeted Therapies Epidemiology Segmentation The BAFF- and APRIL-targeted therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for BAFF- and APRIL-targeted Therapies Total Eligible Patient Pool in Selected Indications for BAFF- and APRIL-targeted Therapies Total Treated Cases in Selected Indications for BAFF- and APRIL-targeted Therapies BAFF- and APRIL-targeted Therapies Report Metrics Details Study Period 2020–2034 BAFF- and APRIL-targeted Therapies Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report IgA nephropathy (IgAN), lupus nephritis, myasthenia gravis, systemic lupus erythematosus (SLE), Sjögren's syndrome, and other B-cell-mediated autoimmune conditions Key BAFF- and APRIL-targeted Therapies Companies Vera Therapeutics, RemeGen, Aurinia Pharmaceuticals, and others Key BAFF- and APRIL-targeted Therapies Atacicept, Telitacicept, AUR200, and others Scope of the BAFF- and APRIL-targeted Therapies Market Report BAFF- and APRIL-targeted Therapies Therapeutic Assessment: BAFF- and APRIL-targeted Therapies current marketed and emerging therapies BAFF- and APRIL-targeted Therapies Market Dynamics: Conjoint Analysis of Emerging BAFF- and APRIL-targeted Therapies Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, BAFF- and APRIL-targeted Therapies Market Access and Reimbursement Discover more about BAFF- and APRIL-targeted therapies in development @ BAFF- and APRIL-targeted Therapies Clinical Trials Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary 4. Key Events 5. Epidemiology and Market Forecast Methodology 6. BAFF- and APRIL-targeted Therapies Market Overview at a Glance in the 7MM 6.1. Market Share (%) Distribution by Therapies in 2025 6.2. Market Share (%) Distribution by Therapies in 2034 6.3. Market Share (%) Distribution by Indications in 2025 6.4. Market Share (%) Distribution by Indications in 2034 7. BAFF- and APRIL-targeted Therapies: Background and Overview 7.1. Introduction 7.2. Potential of BAFF- and APRIL-targeted Therapies in Different Indications 7.3. Clinical Applications of BAFF- and APRIL-targeted Therapies 8. Target Patient Pool of BAFF- and APRIL-targeted Therapies 8.1. Assumptions and Rationale 8.2. Key Findings 8.3. Total Cases of Selected Indication for BAFF- and APRIL-targeted Therapies in the 7MM 8.4. Total Eligible Patient Pool of Selected Indication for BAFF- and APRIL-targeted Therapies in the 7MM 8.5. Total Treatable Cases in Selected Indication for BAFF- and APRIL-targeted Therapies in the 7MM 9. Emerging Therapies 9.1. Key Competitors 9.2. Atacicept: Vera Therapeutics 9.2.1. Product Description 9.2.2. Other developmental activities 9.2.3. Clinical development 9.2.4. Safety and efficacy 9.3. Telitacicept: RemeGen 9.3.1. Product Description 9.3.2. Other developmental activities 9.3.3. Clinical development 9.3.4. Safety and efficacy List to be continued in the report 10. BAFF- and APRIL-targeted Therapies: Seven Major Market Analysis 10.1. Key Findings 10.2. Market Outlook 10.3. Conjoint Analysis 10.4. Key Market Forecast Assumptions 10.4.1. Cost Assumptions and Rebates 10.4.2. Pricing Trends 10.4.3. Analogue Assessment 10.4.4. Launch Year and Therapy Uptakes 10.5. Total Market Sizes of BAFF- and APRIL-targeted Therapies by Indications in the 7MM 10.6. The United States Market Size 10.6.1. Total Market Size of BAFF- and APRIL-targeted Therapies in the United States 10.6.2. Market Size of BAFF- and APRIL-targeted Therapies by Indication in the United States 10.6.3. Market Size of BAFF- and APRIL-targeted Therapies by Therapies in the United States 10.7. EU4 and the UK 10.7.1. Total Market Size of BAFF- and APRIL-targeted Therapies in EU4 and the UK 10.7.2. Market Size of BAFF- and APRIL-targeted Therapies by Indications in EU4 and the UK 10.7.3. Market Size of BAFF- and APRIL-targeted Therapies by Therapies in EU4 and the UK 10.8. Japan 10.8.1. Total Market Size of BAFF- and APRIL-targeted Therapies Inhibitors in Japan 10.8.2. Market Size of BAFF- and APRIL-targeted Therapies by Indications in Japan 10.8.3. Market Size of BAFF- and APRIL-targeted Therapies by Therapies in Japan 11. SWOT Analysis 12. KOL Views 13. Unmet Needs 14. Market Access and Reimbursement 15. Appendix 15.1. Bibliography 15.2. Report Methodology 16. DelveInsight Capabilities 17. Disclaimer 18. About DelveInsight Related Reports Sjogren's Syndrome Market Sjogren's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Sjogren's syndrome companies, including Advanz Pharma, Daiichi Sankyo, Resolve Therapeutics, GlaxoSmithKline, VIELABIO, RemeGen, Bristol Myers Squibb, TearSolutions, Pfizer Inc., AstraZeneca plc, Novartis AG, Sanofi S.A., Roche Holding AG, Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Biogen Inc., Amgen Inc., Celgene Corporation, Genentech, Inc., Boehringer Ingelheim International GmbH, Takeda Pharmaceutical, Gilead Sciences, Inc., Merck & Co., Vertex Pharmaceuticals, Bayer AG, among others. Systemic Lupus Erythematosus Market Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SLE companies, including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others. Lupus Nephritis Market Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including Hoffmann-La Roche, Chugai Pharmaceutical, Novartis Pharmaceuticals, among others. IgA Nephropathy Market IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IgAN companies, including Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data